Document:

EX-10.27

 Exhibit 10.27 
 [***] indicates material that has been omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission. A complete copy of this agreement, including redacted
portions so indicated, has been filed separately with the Securities Exchange Commission. 
 InvibioTM 

biomaterial solutions 
 INVIBIO LIMITED 
 AND 

LDR MEDICAL 
  

 
 LIMITED TERRITORY

 AGREEMENT FOR THE SUPPLY OF 
 STOCK SHAPE 
 POLYARYLETHERETHERKETONE 

 
  

 

  

					
	Confidential	  	Page 1 of 27	  	

 CONTENTS 

 

					
	Clause	  	Page	 
	 1. INTERPRETATION
	  	 	4	  
	 2. SUPPLY OF THE STOCK SHAPE
	  	 	5	  
	 3. TERM
	  	 	5	  
	 4. ORDERS
	  	 	5	  
	 5. DELIVERY
	  	 	6	  
	 6. RISK
	  	 	7	  
	 7. TITLE
	  	 	7	  
	 8. IMPORT AND EXPORT LICENCES
	  	 	7	  
	 9. CHANGES
	  	 	7	  
	 10. USE OF THE STOCK SHAPE
	  	 	7	  
	 11. PRICES
	  	 	8	  
	 12. PAYMENT
	  	 	8	  
	 13. [***]
	  	 	8	  
	 14. THIRD PARTY RIGHTS
	  	 	9	  
	 15. SAFETY
	  	 	9	  
	 16. WARRANTY AND LIABILITY
	  	 	9	  
	 17. INTELLECTUAL PROPERTY
	  	 	10	  
	 18. CONSULTANCY AND OTHER ACTIVITIES
	  	 	11	  
	 19. INSURANCE
	  	 	11	  
	 20. INDEMNITY
	  	 	11	  
	 21. TERMINATION
	  	 	12	  
	 22. CONSEQUENCES OF TERMINATION
	  	 	12	  
	 23. FORCE MAJEURE
	  	 	12	  
	 24. CONFIDENTIALITY
	  	 	13	  
	 25. COSTS
	  	 	14	  
	 26. ENTIRE AGREEMENT
	  	 	14	  
	 27. GENERAL
	  	 	14	  
	 28. ASSIGNMENT
	  	 	15	  
	 29. NOTICES
	  	 	15	  
	 30. GOVERNING LAW
	  	 	16	  
	 31. JURISDICTION
	  	 	16	  

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  

					
	Confidential	  	Page 2 of 27	  	

 Schedule 1 
  

					
	 Part I The Specification
	  	 	17	  
		
	 Part II The Manufacturing Definition
	  	 	18	  
		
	 Schedule 2 THE BUYER PRODUCTS 
	  	 	19	  
		
	 Schedule 3 THE TRADEMARK SUB—LICENCE 
	  	 	20	  

  

					
	Confidential	  	Page 3 of 27	  	

 THIS AGREEMENT IS MADE
                             2003 
 BETWEEN: 
  

	(1)	INVIBIO LIMITED, a company incorporated in England and Wales (registered no. 4088050), whose principal place of business is at Technology Centre, Hillhouse
International, Thornton Cleveleys, Lancashire, FY5 4QD (the “Supplier”); and 

  

	(2)	LDR MEDICAL a company incorporated in France, SIREN N° 433924529 whose principal place of business is at Technopole de l’aube—BP 2, 10902 Troyes
Cedex9. 

 INTRODUCTION: 
  

	(A)	The Supplier is engaged in the manufacture and sale of the Stock Shape (as defined below). 

 

	(B)	The Buyer wishes to purchase the Stock Shape from the Supplier, and the Supplier is willing to supply the Buyer with the Stock Shape, both on the terms and conditions
set out in this Agreement. 

 THE PARTIES AGREE as follows: 

 

	1.	INTERPRETATION 

  

	1.1	In this Agreement: 

“Biomaterials” means the Supplier’s specific grade of PEEK-OPTIMA polyaryletheretherketone, manufactured to the
Specification; 
 “Buyer Products” means the products listed in Schedule 2; 

“Group” means the Supplier, its subsidiaries and fellow subsidiaries of the Supplier’s holding company, from time to
time; 
 “Net Invoice Price” means the gross invoice price of a Buyer Product before deduction of any discounts
or allowances given and after deduction of any charges for freight or insurance and any tax or duty charged to the purchaser; 

“Order” means an order in writing for a quantity of the Stock Shape received by the Supplier from the Buyer; 

“Product Group” means all Buyer Products belonging to any given implant product line, mainly differing in sizes;

 “Specification” means the selling specification for the Biomaterials set out in Schedule 1, Part I;

 “Stock Shape” means the Biomaterials melt processed so as to form an extruded rod stock; 

“Supply Manufacturing Definition” means the dimensional, mechanical and physical properties of the Stock Shape, as set
out in Schedule 1, Part II; 
 “Territory” means every country worldwide with the exception of the United States
of America; 
 “Trademark Sub-licence” means a sub-licence between the Supplier and the Buyer in the form set
out at Schedule 3; 

  

					
	Confidential	  	Page 4 of 27	  	

 “Year” means each successive period of 12 months commencing on the date of
this Agreement; and 
 “€” means Euro. 

 

	1.2	In this Agreement, a reference to: 

  

	 	1.2.1	a document is a reference to that document as modified from time to time; 

  

	 	1.2.2	a person includes a reference to a corporation, body corporate, association or partnership; 

 

	 	1.2.3	a person includes a reference to that person’s legal personal representatives, successors and permitted assigns; 

 

	 	1.2.4	a reference to a “subsidiary” is to be construed in accordance with section 736 of the Companies Act 1985; 

 

	 	1.2.5	the singular includes the plural and vice versa (unless the context otherwise requires); and 

 

	 	1.2.6	a Clause or Schedule, unless the context otherwise requires, is a reference to a clause of or schedule to this Agreement. 

 

	1.3	The headings in this Agreement do not affect its interpretation. 

  

	2.	SUPPLY OF THE STOCK SHAPE 

  

	2.1	The Buyer shall purchase from the Supplier and the Supplier shall supply to the Buyer the Stock Shape on the terms of this Agreement. For the avoidance of doubt, all
sales of the Stock Shape during the Term shall be governed by the terms of this Agreement. 

  

	3.	TERM 

  

	3.1	This Agreement has a term of 3 Years (the “Term”) from the date of this Agreement, unless terminated earlier pursuant to Clause 21. Not less than 3
months prior to the end of the Term, the parties shall enter into good faith negotiations regarding the possible continuing supply of the Stock Shape on mutually agreeable terms, including as to price. 

 

	4.	ORDERS 

  

	4.1	The Buyer may submit an Order as and when required. The Buyer is not entitled to cancel an Order for the Stock Shape once it has been submitted to the Supplier.

  

	4.2	Each Order for the Stock Shape shall be for not less than a minimum quantity of 5 meters. Orders will only be accepted in full meter quantities.

  

	4.3	The Buyer shall with its first Order and then on each anniversary of the date of this Agreement provide a non-binding, written forecast setting out Buyer’s
anticipated requirements for the Stock Shape for the next Year. 

  

	4.4	The Supplier shall, as soon as reasonably practicable after receipt, notify the Buyer whether it is willing to accept an Order and if it is, the anticipated delivery
date for that Order. As at the date of this Agreement, the Supplier would normally expect the anticipated delivery date to be no later than 90 days from the date of receipt of an Order for an amount of the Stock Shape up to 100 meters.

  

					
	Confidential	  	Page 5 of 27	  	

	4.5	If the Supplier accepts an Order, but subsequently is unable to deliver the quantity of the Stock Shape requested in an Order by the anticipated delivery date notified
in accordance with Clause 4.3, the Supplier shall promptly notify the Buyer accordingly and specify a revised anticipated delivery date. 

  

	5.	DELIVERY 

  

	5.1	The Supplier is deemed to have fulfilled its contractual obligations in respect of each delivery provided that the quantity of Stock Shape actually delivered is neither
1 % more nor 1 % less than the quantity specified in the Order. 

  

	5.2	Delivery shall be FCA Incoterms 2000 at the Supplier’s premises in Thornton Cleveleys, England. The cost of delivery is included in the price of the Stock Shape.
For the avoidance of doubt, all costs relating to the shipment of each consignment of the Stock Shape from the moment of delivery are for the Buyer’s account. The Supplier shall advise the Buyer when each Consignment is ready for collection.

  

	5.3	The Buyer shall give the Supplier, within 30 days of the date of the delivery of each consignment of the Stock Shape, written confirmation that it has inspected and
tested the consignment and that it is satisfied that the consignment wholly conforms to the Supply Manufacturing Definition. 

  

	5.4	If the Buyer fails to give notice of conformity with the Supply Manufacturing Definition in accordance with Clause 5.3, it shall in any event be deemed to have accepted
the consignment in full. 

  

	5.5	The Buyer may reject all or part of any consignment of the Stock Shape only on the ground that the consignment or part thereof does not conform to the Supply
Manufacturing Definition and only by giving the Supplier written notice of such rejection immediately on discovery of such lack of conformity, including full details of the reason for such rejection, but in any event only within 30 days of the
delivery of the consignment. 

  

	5.6	Should the Buyer give such notice of rejection under Clause 5.5, the parties shall cooperate to investigate and determine the cause of the non-conformity.

  

	5.7	Notwithstanding the giving of notice of rejection under Clause 5.5 the Buyer shall pay the purchase price and all insurance and freight charges for the consignment,
provided however that if, after the investigations required by Clause 5.6, the Supplier is reasonably satisfied that the rejection was justified, the Supplier shall reimburse the purchase price and all other charges (or part thereof in direct
proportion to the percentage of the consignment which the Buyer rejected). 

  

	5.8	If notice of rejection is given under Clause 5.5, the Buyer shall be entitled to withhold that part of the purchase price and that part of the insurance and freight
charges relating to that portion of the consignment that is rejected, provided however that if, after the investigations required by clause 5.6, the Supplier is reasonably satisfied that the rejection was not justified, the Buyer shall pay all
previously withheld amounts. 

  

	5.9	If the Buyer refuses or fails to take delivery of a consignment of the Stock Shape (or any part thereof) tendered in accordance with this Agreement or fails to take any
action necessary on its part for delivery and/or shipment of the Stock Shape, the Supplier is entitled to terminate the relevant Order with immediate effect, to dispose of the Stock Shape as the Supplier may determine and to recover from the Buyer
any loss and additional costs incurred as a direct result of such refusal or failure (including, without limitation, storage costs from the date of delivery). 

  

					
	Confidential	  	Page 6 of 27	  	

	6.	RISK 

  

	6.1	Risk in the Stock Shape passes on delivery. 

  

	6.2	From the time of delivery until property in a consignment of the Stock Shape passes to the Buyer in accordance with Clause 7 the Buyer shall use its best efforts to
insure the Stock Shape for its full value with reputable insurers. Upon request, the Buyer shall use reasonable endeavours to have the Supplier’s interest in the Stock Shape noted on the insurance policy. Until property in the consignment of
the Stock Shape passes to the Buyer the Buyer shall hold the proceeds of any claim on the insurance policy on trust for the Supplier and on demand shall immediately account to the Supplier with those proceeds. 

 

	7.	TITLE 

 Notwithstanding
delivery and passing of risk each consignment of the Stock Shape shall remain the property of the Supplier until the Buyer pays to the Supplier the agreed price for the consignment (together with any accrued interest). 

 

	8.	IMPORT AND EXPORT LICENCES 

Clause deleted. 
  

	9.	CHANGES 

 The Supplier may
[***] upon giving not less than [***] prior written notice to the Buyer. The Buyer shall be entitled, during that notice period, to [***] for delivery at the earliest reasonably practicable date for a quantity of the Stock Shape manufactured to the
Supply Manufacturing Definition then in force which shall be no greater than [***] meters. 
  

	10.	USE OF THE STOCK SHAPE 

  

	10.1	The Buyer shall only use the Stock Shape for the manufacture of Buyer Products. The Buyer shall not use any other polyaryletheretherketone, other than the Biomaterials,
in the Buyer Products, as defined in Schedule 2. 

  

	10.2	The Buyer shall not sell or otherwise make the Stock Shape available to third parties, except when incorporated into Buyer Products sold in the normal course of
business. 

  

	10.3	The Buyer shall [***]. 

  

	10.4	The Buyer shall [***]. 

  

	10.5	Notwithstanding the provisions of Clauses 10.1 and 10.2, the Buyer may use the Stock Shape for the purpose of developing new products, but no such product may be
implanted into a human body, or commercially developed, without such product being included in Schedule 2. For the avoidance of doubt, the restrictions in Clauses 10.3 and 10.4 shall apply to any such product. 

 

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  

					
	Confidential	  	Page 7 of 27	  	

	10.6	The Buyer shall not, other than to the extent strictly necessary for the purpose of the manufacture of Products, alter the physical or chemical characteristics of the
Stock Shape. 

  

	10.7	The Supplier shall be entitled to discontinue the supply of the Stock Shape on [***] prior written notice, including the cancellation of any Orders then already
accepted from the Buyer, in the event that the Supplier has reasonable grounds for concluding (based on documentary evidence) that the Buyer has acted in breach of this Clause 10. The Buyer shall have [***] from the date of receipt of such a notice
to prove to the Supplier’s reasonable satisfaction that it has not acted in breach of this Clause 10, or, if it has acted in breach, to rectify that breach. Should the Buyer fail to satisfy the Supplier or so rectify the breach (as the case may
be) the Supplier shall be entitled to terminate this Agreement with immediate effect. 

  

	11.	PRICES 

  

	11.1	The price to be paid by the Buyer to the Supplier for all consignments of the Stock Shape delivered in the year 2003 is for grade LTlR20 € [***] and for grade
LTlR30 € [***]. 

  

	11.2	The Supplier shall be entitled to increase the price per meter for the Stock Shape once in the year 2003 and once in each subsequent calendar year during the term of
this Agreement, provided however no single annual increase shall be by more than [***]% The Supplier shall give the Buyer not less than 60 days’ written notice of any change in the Price. 

 

	11.3	Unless otherwise specified, VAT and any other tax or duty payable by the Buyer shall be added to the price payable for each consignment of the Stock Shape.

  

	12.	PAYMENT 

  

	12.1	The Supplier shall, on the date of delivery of a consignment of the Stock Shape, invoice the Buyer for that consignment. 

 

	12.2	The Buyer shall, unless otherwise agreed, pay each invoice in full within 45 days of the date of the invoice in cleared funds to the bank account notified from time to
time by the Supplier. The Supplier may suspend the supply of the Stock Shape to the Buyer where any amounts are overdue under this Agreement until all such amounts have been paid. The Buyer may not by reason of any set-off, counterclaim, abatement
or analogous deduction withhold payment of any amount due to the Supplier under this Agreement. 

  

	12.3	The Buyer shall pay interest on all overdue amounts at the rate of 1 % over the base rate of Barclays Bank pic from time to time, from the due date for payment
until receipt by the Supplier of the full amount (including any accrued interest) whether before or after judgement. 

  

	12.4	The Buyer shall pay to the Supplier not later than [***] after the date of this Agreement the amount of € [***] (the “[***]”). 

 

	13.	[***] 

 [***] 

 

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  

					
	Confidential	  	Page 8 of 27	  	

	14.	THIRD PARTY RIGHTS 

  

	14.1	If it is alleged at any time that the Stock Shape infringes the rights of any third party or if in the Supplier’s reasonable opinion such an allegation is likely
to be made, the Supplier may at its option and at its own expense: 

  

	 	14.1.1	procure for the Buyer the right to continue to use the Stock Shape; or 

  

	 	14.1.2	repurchase the Stock Shape at the price paid by the Buyer less depreciation at the rate the Supplier applies to its own equipment. 

 

	14.2	The Buyer shall notify the Supplier immediately of any claim made or action brought or threatened alleging infringement of the rights of any third party. The Supplier
shall have control over and shall conduct any such proceedings in such manner as it shall determine. The Buyer shall provide all such reasonable assistance as the Supplier may request. The cost of any such proceedings shall be borne by the Supplier.

  

	15.	SAFETY 

  

	15.1	The parties shall give each other prompt written notice of any adverse facts or issues which come to their attention relating to the safety or efficacy the Stock Shape
or a Buyer Product. Notwithstanding any other provisions of this Agreement, in the event that Supplier reasonably believes that any such adverse facts or issues relating to the safety or efficacy of the Stock Shape or Buyer Products may result in
liability to Supplier, Supplier may, at its sole discretion, immediately terminate this Agreement. 

  

	15.2	The Buyer shall provide the Supplier at least once each Year with a comprehensive summary of any relevant reports to or of the United States Food and Drug
Administration, the Medicine Controls Agency or any other competent regulatory or notifying body or any Buyer complaints relating to any of the Products or the Stock Shape of which the Buyer is aware. 

 

	16.	WARRANTY AND LIABILITY 

  

	16.1	The Supplier warrants that the Stock Shape will, when delivered: 

  

	 	16.1.1	comply with the Supply Manufacturing Definition; and 

  

	 	16.1.2	have been manufactured, packaged, handled and stored by the Supplier with reasonable skill, competence, care and attention. 

 

	16.2	The Supplier makes no representations and gives no warranties as to the suitability or otherwise of the Stock Shape for use in the manufacture of the Buyer Products or
any other application. For the avoidance of doubt, it shall be the sole responsibility of the Buyer to determine the suitability of the Stock Shape for use in the manufacture of the Buyer Products or any other application. 

 

	16.3	The warranties in Clause 16.1 are given on the following conditions: 

  

	 	16.3.1	that the Supplier is not liable for a defect in the Stock Shape caused by fair wear and tear, abnormal or unsuitable conditions of storage or use or an act, neglect or
default of the Buyer or a third party; and 

  

	 	16.3.2	that the Supplier is not liable for a defect in the Stock Shape unless it is notified to the Supplier within 30 days of the date of delivery or, if the defect would not
be apparent on reasonable inspection before the Stock Shape is incorporated into a Buyer Product within 90 days of the date of delivery. 

  

					
	Confidential	  	Page 9 of 27	  	

	16.4	The Supplier is not liable for any shortages in quantity delivered in excess of those permitted by Clause 5.1 unless the Buyer notifies the Supplier of a claim within
14 days of receipt of the Stock Shape. 

  

	16.5	If the Supplier is liable under the warranties in Clause 16.1 or under Clause 16.3, the Supplier’s only obligation is, at its option, to: 

 

	 	16.5.1	make good any shortage or non-delivery; 

  

	 	16.5.2	replace or repair any quantity of the Stock Shape which IS damaged or defective; or 

 

	 	16.5.3	refund to the Buyer the amount paid by the Buyer for the quantity of the Stock Shape the subject of the claim, together with the relevant transportation costs.

  

	16.6	Except as set out in this Clause 16, all conditions, warranties and representations, expressed or implied by (i) statute, (ii) common law or
(iii) otherwise, in relation to the Stock Shape are excluded. 

  

	16.7	The Supplier is not liable to the Buyer, whether for negligence, breach of contract, misrepresentation or otherwise, for: 

 

	 	16.7.1	loss or damage incurred by the Buyer as a result of third party claims; 

  

	 	16.7.2	indirect or consequential damage suffered by the Buyer, including, without limitation, loss of profit, goodwill, business opportunity or anticipated saving.

  

	16.8	The entire liability of the Supplier under or in connection with the supply of the Stock Shape, whether for negligence, breach of contract, misrepresentation or
otherwise, is limited, in respect of each event or series of connected events, to the cost of the defective, damaged or undelivered quantity of the Stock Shape which gives rise to such liability as determined by the net price invoiced to the Buyer.

  

	16.9	Nothing in this Agreement shall operate to exclude or restrict the Supplier’s liability for: 

 

	 	16.9.1	death or personal injury resulting from negligence; 

  

	 	16.9.2	breach of the obligations arising from section 12 of the Sale of Goods Act 1979; or 

 

	 	16.9.3	fraud. 

  

	16.10	The invalidity, illegality or unenforceability of the whole or part of this Clause 16 does not affect or impair the continuation in force of the remainder of this
Clause 16. 

  

	17.	INTELLECTUAL PROPERTY 

  

	17.1	The Supplier is the sole owner of all intellectual property and any other proprietary rights in and to the Biomaterials and the Stock Shape and the Buyer acknowledges
that this Agreement does not operate to vest any right, title or interest in such rights in the Buyer. 

  

	17.2	The Buyer grants the Supplier a [***] to use any improvements, inventions, ideas or discoveries, whether patentable or not, in relation to the [***]
(“Improvements”) which are developed from time to time by or on behalf of the Buyer, for the purposes of the development, manufacture and sale of the Supplier’s products from time to time. 

 

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  

					
	Confidential	  	Page 10 of 27	  	

	17.3	The Buyer shall promptly disclose full and accurate details to the Supplier of any Improvements (as defined in Clause 17.2). 

 

	17.4	The Buyer shall have a non-exclusive right within the Territory to use the Supplier’s INVIBIO trademark and logo and the Group’s PEEK-OPTIMA trademark but
only in accordance with the terms of the Trademark Sub-Licence set out in Schedule 3. 

  

	17.5	The Buyer shall not at any time assert any rights in the goodwill attaching to any of the Supplier’s or the Group’s trademarks. If the Buyer challenges the
validity of the Supplier’s or the Group’s rights in, to, or the validity of any registrations of the INVIBIO, PEEK, PEEK-OPTIMA, OPTIMA, or any other proprietary rights of the Supplier or of the Group, then the Supplier shall be entitled
to terminate this Agreement and the Trademark Sub—Licence immediately. 

  

	18.	CONSULTANCY AND OTHER ACTIVITIES 

  

	18.1	The Supplier shall provide consultancy services to the Buyer on terms, including as to price, to be agreed between the parties. 

 

	19.	INSURANCE 

  

	19.1	The Buyer warrants to the Supplier that it shall use its best efforts to obtain and once obtained to maintain at all times during the Term insurance with reputable
insurers in respect of any and all liability howsoever and whensoever arising in respect of any claim that the Buyer Products are faulty or defective in an amount reasonably adequate given the nature and purpose of the Buyer Products (the
“Insurance Policy”). Supplier may at its sole discretion, immediately terminate this Agreement if Buyer has not effected such Insurance Policy within twelve (12) months of the effective date of this Agreement.

  

	19.2	The Buyer shall produce to the Supplier as soon as such Insurance Policy is obtained and subsequently at Supplier’s request a letter from its insurers setting out
in reasonably satisfactory detail the levels of cover under the insurance referred to in Clause 19.1 and confirming the validity of that insurance. 

  

	20.	INDEMNITY 

  

	20.1	The Buyer shall indemnify the Supplier on demand against each loss, liability and costs which the Supplier incurs arising out of the supply of the Stock Shape to the
Buyer (including, without limitation, each loss, liability and costs incurred as a result of defending or settling a claim alleging such a liability) provided however that the Supplier shall not be entitled to such indemnification where such a claim
arises solely from any failure of the Stock Shape to comply with the Supply Manufacturing Definition or solely from any breach of third party intellectual property rights arising from the Supplier’s manufacture of the Stock Shape.

  

	20.2	The Supplier shall notify the Buyer in writing within a reasonable period of all claims for which the Buyer is liable to indemnify the Supplier under Clause 20.1 above.
The Supplier shall not admit any liability nor make any payment, settlement, or compromise in respect of any such claim without the prior written consent of the Buyer. The Buyer may if it so chooses and by prior written notice to the Supplier, in
the name of the Supplier, conduct the defence, settlement, compromise, counter claim and any third party proceedings in respect of any such claims provided that the Buyer shall keep the Supplier regularly informed as to the conduct thereof and that
the Buyer may not admit liability in respect of or settle any such proceedings without first obtaining the Supplier’s written consent. 

  

					
	Confidential	  	Page 11 of 27	  	

	21.	TERMINATION 

  

	21.1	A party (the “Initiating Party”) may terminate this Agreement with immediate effect by written notice to the other party (the “Breaching
Party”) on or at any time after the occurrence of an event specified in Clause 21.2 in relation to the Breaching Party. 

  

	21.2	The events are: 

  

	 	21.2.1	the Breaching Party being in breach of a material obligation under this Agreement and, if the breach is capable of remedy, failing to remedy the breach within 30 days
starting on the day after receipt of written notice from the Initiating Party. That written notice shall contain full details of the breach and shall further require the Breaching Party to remedy the breach and state that a failure to remedy the
breach may give rise to termination under Clause 21. 1. For the purposes of this Clause 21.2.1 a breach is capable of remedy if time is not of the essence in performance of the obligation and if the Breaching Party can comply with the obligation
within the 30 day period; 

  

	 	21.2.2	the Breaching Party passing a resolution for its winding up or a court of competent jurisdiction making an order for the Breaching Party’s winding up or
dissolution; 

  

	 	21.2.3	the making of an administration order in relation to the Breaching Party or the appointment of a receiver over, or an encumbrancer taking possession of or selling, an
asset of the Breaching Party; or 

  

	 	21.2.4	a change of control of the Breaching Party; in this Clause 21.2.4, “control” means the ability to direct the affairs of another whether by way of
contract, ownership of shares or otherwise howsoever. 

  

	21.3	This Agreement may be terminated at any time during the Term by written mutual agreement between the parties. 

 

	22.	CONSEQUENCES OF TERMINATION 

  

	22.1	Termination of this Agreement does not affect a party’s accrued rights and obligations at the date of termination. 

 

	22.2	Each party’s further rights and obligations shall cease immediately on termination except that: 

 

	 	22.2.1	Clauses 10, 12.2, 12.3, 15, 16, 17, 20, 24, 30 and 31, together with those Clauses the survival of which is necessary for the interpretation or enforcement of this
Agreement, shall survive termination of this Agreement, and shall continue in full force and effect. 

  

	23.	FORCE MAJEURE 

  

	23.1	If a party (the “Affected Party”) is prevented, hindered or delayed from or in performing any of its obligations under this Agreement (other than a
payment obligation) by a Force Majeure Event: 

  

	 	(a)	the Affected Party’s obligations under this Agreement are suspended while the Force Majeure Event continues and to the extent that it is prevented, hindered or
delayed; 

  

	 	(b)	as soon as reasonably possible after the start of the Force Majeure Event the Affected Party shall notify the other party in writing of the Force Majeure Event, the
date on which the Force Majeure Event started and the effects of the Force Majeure Event on its ability to perform its obligations under this Agreement; 

  

					
	Confidential	  	Page 12 of 27	  	

	 	(c)	if the Affected Party does not comply with Clause 23. I (b) it forfeits its rights under Clause 23.1(a); 

 

	 	(d)	the Affected Party shall make all reasonable efforts to mitigate the effects of the Force Majeure Event on the performance of its obligations under this Agreement; and

  

	 	(e)	as soon as reasonably possible after the end of the Force Majeure Event the Affected Party shall notify the other party in writing that the Force Majeure Event has
ended and resume performance of its obligations under this Agreement. 

  

	23.2	In this Clause 23, “Force Majeure Event” means an event beyond the reasonable control of the Affected Party including, without limitation, strike,
lock-out, labour dispute, act of God, war, riot, civil commotion, malicious damage, compliance with a law or governmental order, rule, regulation or direction, accident, breakdown of plant or machinery, fire, flood and storm.

  

	24.	CONFIDENTIALITY 

  

	24.1	In this Clause 24, “Confidential Information” means all confidential information disclosed (whether in writing, orally or by another means and whether
directly or indirectly) by a party (the “Disclosing Party”) to the other party (the “Receiving Party”) whether before or after the date of this Agreement including, without limitation, information relating to the
financial arrangements set out in this Agreement, the Disclosing Party’s products, operations, processes, plans or intentions, product information, know-how, design rights, trade secrets, market opportunities and business affairs.

  

	24.2	During the term of this Agreement and after termination or expiration of this Agreement for any reason the Receiving Party: 

 

	 	24.2.1	may not use Confidential Information for a purpose other than the performance of its obligations under this Agreement; 

 

	 	24.2.2	may not disclose Confidential Information to a person except with the prior written consent of the Disclosing Party or in accordance with Clauses 24.3 and 24.4; and

  

	 	24.2.3	shall make every effort to prevent the use or disclosure of Confidential Information. 

 

	24.3	During the term of this Agreement the Receiving Party may disclose Confidential Information to any of its directors, other officers, employees and sub-contractors (a
“Recipient”) to the extent that disclosure is reasonably necessary for the purposes of this Agreement. 

  

	24.4	The Receiving Party shall ensure that a Recipient is made aware of and complies with the Receiving Party’s obligations of confidentiality under this Agreement as
if the Recipient was a party to this Agreement. 

  

	24.5	Clauses 24.1 to 24.4 do not apply to Confidential Information which: 

  

	 	24.5.1	is at the date of this Agreement, or at any time after that date becomes, publicly known other than by the Receiving Party’s or Recipient’s breach of this
Agreement; or 

  

					
	Confidential	  	Page 13 of 27	  	

	 	24.5.2	can be shown by the Receiving Party to the Disclosing Party’s reasonable satisfaction to have been known by the Receiving Party before disclosure by the Disclosing
Party to the Receiving Party. 

  

	24.6	On termination of this Agreement both parties shall return to the other party forthwith all Confidential Information received by them including all notes, memoranda or
other stored information of any kind summarising any of the Confidential Information together with all relevant samples and models it has in its possession pursuant to this Agreement. 

 

	25.	COSTS 

 Except where this
Agreement provides otherwise, each party shall pay its own costs relating to the negotiation, preparation, execution and implementation by it of this Agreement and of each document referred to in it. 

 

	26.	ENTIRE AGREEMENT 

  

	26.1	This Agreement constitutes the entire agreement, and supersedes any previous agreements, between the parties relating to the subject matter of this Agreement.

  

	26.2	Each party acknowledges that it has not relied on or been induced to enter this Agreement by a representation other than those expressly set out in this Agreement.

  

	26.3	A party is not liable to the other party for a representation that is not set out in this Agreement. 

 

	26.4	This Clause 26 does not affect a party’s liability in respect of a fraudulent misrepresentation. 

 

	27.	GENERAL 

  

	27.1	A variation of this Agreement is valid only if it is in writing and signed by a duly authorised representative on behalf of each party. 

 

	27.2	A failure to exercise or delay in exercising a right or remedy provided by this Agreement or by law does not constitute a waiver of the right or remedy or a waiver of
other rights or remedies. No single or partial exercise of a right or remedy provided by this Agreement or by law prevents further exercise of the right or remedy or the exercise of another right or remedy. 

 

	27.3	Except where this Agreement provides otherwise the rights and remedies contained in this Agreement are cumulative and not exclusive of rights or remedies provided by
law. 

  

	27.4	Each party shall at its own cost do and execute, or arrange for the doing and executing of, each necessary act, document and thing reasonably within its power to
implement this Agreement. 

  

	27.5	No provision of this Agreement creates a partnership between the parties or makes one party the agent of the other for any purpose. Neither party has the authority or
power to bind, to contract in the name of or to create a liability for the other in any way for any purpose. There is not, as at the date of this Agreement, and never has been, any form of common ownership, common control, common management or any
other affiliation between the parties. 

  

	27.6	If a provision of this Agreement is invalid, illegal or unenforceable the parties shall promptly enter into good faith negotiations to agree a mutually satisfactory
provision to be substituted for that provision and which as nearly as possible gives effect to their intentions as expressed in this Agreement. This Agreement shall terminate automatically without notice if the parties fail to agree on a substitute
provision within one month of the start of those negotiations. During those negotiations, the parties’ obligations under this Agreement are suspended. 

  

					
	Confidential	  	Page 14 of 27	  	

	27.7	A person who is not a party to this Agreement has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Agreement but this does
not affect any right or remedy of a third party which exists or is available apart from that Act. 

  

	27.8	This Agreement may be executed in any number of counterparts, each of which is an original and all of which together evidence the same agreement.

  

	28.	ASSIGNMENT 

 A party may
not assign or transfer or purport to assign or transfer a right or obligation under this Agreement without having first obtained the other party’s written consent provided however that the Supplier may assign this Agreement in whole or in part
to any member of the Group. Each party is entering into this Agreement for its benefit and not for the benefit of another person. 
  

	29.	NOTICES 

  

	29.1	A notice under or in connection with this Agreement (a “Notice”): 

 

	 	29.1.1	shall be in writing; and 

  

	 	29.1.2	may be delivered personally or sent by first class post pre-paid recorded delivery (and air mail if overseas) to the party due to receive the Notice to the address
specified in Clause 29.3 or to another address, or person, specified by that party by not less than 7 days’ written notice to the other party received before the Notice was despatched. 

 

	29.2	The address referred to in Clause 29.1.2 is: 

  

	 	29.2.1	In the case of the Buyer, to: 

  

	 	    	LDR MEDICAL, TECHNOPOLE DE L’ AU BE—BP 2, 10902 TROYES CEDEX9. 

  

	 	    	Marked for the attention of Christophe Lavigne, President; 

  

	 	29.2.2	in the case of the Supplier, to: 

  

	 	    	Invibio Limited 

  

	 	    	Technology Centre, Hillhouse International, Thornton Cleveleys, 

  

	 	    	Lancashire, United Kingdom, FY5 4QD 

   Marked for the attention of the Company Secretary, with a copy to the Commercial Director at the same address. 
  

	29.3	Unless there is evidence that it was received earlier, a Notice is deemed given: 

 

	 	29.3.1	if delivered personally, when left at the address referred to in clause 29.2; 

 

	 	29.3.2	if sent by registered courier service, two days after sending it; and 

  

	 	29.3.3	if sent by air mail, six days after posting it. 

  

					
	Confidential	  	Page 15 of 27	  	

	30.	GOVERNING LAW 

 This
Agreement and all matters arising from or connected with it are governed by English law. 
  

	31.	JURISDICTION 

  

	31.1	The courts of England have exclusive jurisdiction to settle any dispute arising from or connected with this Agreement (a “Dispute”). 

 

	31.2	The Buyer agrees that the documents which start any proceedings relating to a Dispute and any other documents required to be served in relation to such proceedings may
be served on it in accordance with Clause 29. Those documents may, however, be served in any other manner allowed by law. 

  

					
	Confidential	  	Page 16 of 27	  	

					
	PEEK-OPTlMA®	  	InvibioTM	  	PEEK-OPTlMA® LT 1
			
	 Specifications

MANUAL
 ISSUE I 
	  	biomaterial solutions	  	 Page 1 of 1
 Rev: 0

23rd October 2001

 SCHEDULE 1 PART 1 
 THE SPECIFICATION 
  

			
	GRADE PEEK-OPTIMA® LT 1	  	SPECIFICATION Ref. INV 01                

  

							
	 PROPERTY
	  	TEST METHOD	 	        UNITS        	 	SPECIFICATION
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]

 Notes: 
  

	1.	Moisture is measured at time of packing. 

 PEEK-OPTIMA® is hygroscopic so may absorb moisture during storage
and therefore should be dried before use 
  

	2.	Standard Granule Cut Specification 

  

	 	(a)	Dimensions, length 2.0—4.0 mm, diameter 2.0—3.5 mm. 

  

	 	(b)	Granules to be crystalline in appearance and essentially of uniform cut and colour. 

 

	3.	 Each batch will have FTIR & GPC analysis to confirm that it displays the typical characteristics of PEEK-OPTIMA® LTI 

 Granules are dusted with Calcium Stearate as a processing lubricant in the range 0.001—0.05 % 
 SPECIFICATION APPROVAL 
  

							
	Quality Assurance & Laboratory Manager:	 		 	/s/ Margaret Such
	Date: 23rd October 2001	 		 		 	

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  

					
	Confidential	  	Page 17 of 27	  	

 PART II 
 Supply Manufacturing Definition 
 PEEK-OPTIMA L Tl Extruded Rod. 

Grade LT1R20 
 Diameter 20mm +0.2mm! + 1.1
mm 
 Sampling and testing: 

The tests shown below shall be performed by supplier on material taken from the start and end of each production batch. The batch shall meet the
requirements of this Supply Manufacturing Definition when the results of these tests agree with the values shown below. 
  

							
	 PROPERTY
	  	TEST METHOD	 	        UNITS        	 	SPECIFICATION
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]
	[***]	  	[***]	 	[***]	 	[***]

 Notes: 
  

	1.	The supplied rod may contain levels of black speck intrinsic to all extruded rod stock. 

 

	2.	Some surface discoloration and/or texture is common and this can be removed by machining. 

 

	3.	Gel Permeation Chromatography 

	  	 The material displays the characteristic molecular weight distribution curve for PEEK-OPTIMA® LTI, corresponding with historical GPC data; REF/SPECTRM/LTl/GPC 

  

	4.	FTIR. 

	  	 The material displays the characteristic FTIR spectrum for PEEK-OPTIMA®, corresponding with an historical standard spectrum; REF/SPECTRUM/LTl/FTIR 

 

							
	Margaret Such /s/Margaret Such Date:	 		 	17th September 2001
	Quality Assurance and Laboratory Manager.	 		 		 	

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  

					
	Confidential	  	Page 18 of 27	  	

 SCHEDULE 2 
 THE BUYER PRODUCTS 
  

					
	 Product Group:
	  	 	[	***] 
	 Products:
	  	 	[	***] 
	 Article numbers:
	  	 	[	***] 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  

					
	Confidential	  	Page 19 of 27	  	

 SCHEDULE 3 
 INVIBIO LIMITED 
 AND 

LDR MEDICAL 
  

 
 TRADE MARK
SUB-LICENCE 
  
  

  

					
	Confidential	  	Page 20 of 27	  	

 THIS AGREEMENT is made 31 January 2003 
 BETWEEN: 
  

	(1)	INVIBIO LIMITED, a company incorporated in England and Wales (registered no. 04088050), whose registered office is at Technology Centre, Hillhouse International,
Thornton Cleveleys, Lancashire, FY5 4QD (“Sub-Licensor”); and 

  

	(2)	LDR MEDICAL a company incorporated in France, (registered no SIREN 433 924 529 whose principal place of business is at Technopole de l’ aube—BP 2,
lO902 Troyes Cedex9. 

 WHEREAS: 
  

	(A)	Sub-Licensor is the exclusive licensee under a trade mark licence of Trade Mark Rights in relation to goods. Under the trade mark licence, Sub-Licensor is granted the
right to grant sub-licences of the rights granted to it. 

  

	(B)	Pursuant to a supply agreement dated 31/01/03 between Sub-Licensor and the SubLicensee (the “Supply Agreement”), Sub-Licensor has agreed to sub-licence the
use of the Trade Mark Rights to the Sub-Licensee. 

  

	(C)	Sub-Licensor hereby grants, and Sub-Licensee hereby accepts the grant of, a sub-licence to use the Trade Mark Rights as set out in this Agreement.

 IT IS AGREED as follows: 
  

	1.	INTERPRETATION 

  

	1.1	Unless specifically defined herein, all capitalised terms shall have the same meaning as are given to them in the Supply Agreement. 

 

	1.2	In this Agreement capitalised words and phrases have the following meaning: 

 “Guidelines” means the guidelines, included as an attachment, relating to the use of the Trade Mark and Logo (if any) provided to Sub-Licensee as amended from time to time; 

“Logo” means the Logo form of a Trade Mark from time to time as set out in the Guidelines; 

“Trade Mark” means Sub-Licensor’s and Sub-Licensor’s Groups’ INVIBIO, PEEK-OPTIMA and OPTIMA trademarks
and any other trade marks, registered or unregistered, used in relation to the Stock Shape; 
 “Trade Mark
Rights” means the trade mark applications and registrations, from time to time, for the Trade Mark in various jurisdictions as set out in Schedule I and a reference in this Agreement to a “Trade Mark Right” is a reference to any
and each of the Trade Marks Rights. 
  

	2.	GRANT 

  

	2.1	Subject to the provisions of this Agreement, Sub-Licensor hereby grants to Sub-Licensee [***] to use the Trade Mark Rights in relation to the manufacture, marketing and
sale of Buyer Products in the Territory. 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

  

					
	Confidential	  	Page 21 of 27	  	

	2.2	The licence granted in clause 2.1 of this Agreement is only granted in the jurisdictions within the Territory where the Trade Mark Rights exist as shown in Schedule 1.

  

	2.3	The licence granted in clause 2.1 of this Agreement does not permit the Sub-licensee to use the word “PEEK” other than in conjunction with the word
“OPTIMA”. 

  

	2.4	Sub-Licensor hereby grants the Sub-Licensee a right to copy and reproduce the Logos in relation to use on or in relation to Buyer Products and advertising and
promotional material in relation to the Buyer Products. 

  

	3.	SUB-LICENSEE’S UNDERTAKINGS 

  

	3.1	Except as otherwise provided for in this Agreement, Sub-Licensee acknowledges and agrees that by its use of the Trade Mark pursuant to this Agreement, Sub-Licensee has
not, does not, and shall not, nor shall it be deemed to, acquire at any time now or hereafter, whether by way of this Agreement and/or the use of the Trade Mark, any right, title or interest of any nature whatsoever, in or with respect to the Trade
Mark or the trade mark, “PEEK”. Use of the Trade Mark by Sub-Licensee and all rights derived therefrom in the Trade Mark and in the trade mark, “PEEK” shall enure to the exclusive benefit of the owner of the Trade Mark Rights.
Without prejudice to the foregoing, SubLicensee shall do any act or execute any document to ensure that any rights in the Trade Mark that Sub-Licensee may have acquired shall vest in the owner of the Trade Mark Rights. 

 

	3.2	Sub-licensee shall ensure that the quality of Buyer Products produced and provided under the Trade Mark and/or Logo by Sub-Licensee complies with all relevant
applicable laws, regulations and standards prevailing in the relevant industry. 

  

	3.3	Sub-Licensee shall use the Trade Mark and logo in the form, manner and way indicated in the Guidelines and no other way. For the avoidance of doubt, in the event of
inconsistency between the Guidelines and this Agreement, this Agreement shall prevail. 

  

	3.4	Sub-Licensee shall provide Sub-Licensor, at its reasonable request, with all relevant documents in Sub-licensee’s possession or control (for example, documents
providing evidence of use) that may be required for the protection, renewal and the maintenance in force of the Trade Mark Rights. 

  

	3.5	All advertising and promotional uses of the Trade Mark shall be submitted and approved by Sub-Licensor before use or launch. Where Sub-licensor does not approve such
use within 45 days of receipt of the advertising and promotional material it shall be deemed to have approved such use, provided that such use is otherwise in accordance with this Agreement. Sub-Licensor reserves the right not to approve such
advertising and promotional material, such refusal not to be unreasonable or without a cogent reason. 

  

	3.6	Sub-Licensee shall not use, either during this Agreement or hereafter, any trade mark that is similar to INVIBIO, PEEK, PEEK OPTIMA or OPTIMA in relation to the Buyer
Products or in relation to any similar goods or services. 

  

					
	Confidential	  	Page 22 of 27	  	

	4.	INFRINGEMENT 

  

	4.1	Sub-licensee shall promptly give notice in writing to Sub-Licensor in the event that it becomes aware of: 

 

	 	4.1.1	any infringement or suspected infringement of the Trade Mark in the field of Buyer Products or Logo, generally; and 

 

	 	4.1.2	any claim that the use of the Trade Mark in relation to the Buyer Products, or the use of the Logo, generally, infringes the rights of any third person.

  

	4.2	In the case of any matter within Clause 4.1.2, Sub-Licensor shall have no liability to Sub-Licensee in relation to any infringement of any third party’s rights
caused by the use of the Trade Mark or Logo by Sub-Licensee permitted under this Agreement or otherwise. 

  

	5.	INDEMNITY 

  

	5.1	Sub-Licensee shall indemnify Sub-Licensor against each loss, liability and costs, which Sub-Licensor may incur as a result of any third party claim or action brought
against Sub-Licensor as a result of the use of the Trade Mark and Logo by the Sub-Licensee except insofar as any such claims may arise from: 

  

	 	5.1.1	any breach of this Agreement by the Sub-Licensor; or 

  

	 	5.1.2	any invalidity or defect in the title of the Sub-Licensor to the Trade Mark not caused by any act or default of the Sub-Licensee. 

 

	5.2	Sub-Licensor shall notify Sub-Licensee immediately of any proceedings that are threatened or brought against the Sub-Licensor as a result of the use of the Trade Mark
and shall co-operate with the Sub-Licensee in connection with the defence or settlement of such proceedings. 

  

	6.	TERMINATION 

  

	6.1	Sub-Licensor may terminate this Agreement by notice to Sub-Licensee on or at any time after the occurrence of an event specified in clause 6.2.

  

	6.2	The events are: 

  

	 	6.2.1	termination of the Supply Agreement; 

  

	 	6.2.2	termination of the trade mark licence under which Sub-Licensor derives the right to grant the sub-licence in this Agreement; 

 

	 	6.2.3	Sub-Licensee being in material breach of material obligation under this Agreement and, if the breach is capable of remedy, failing to remedy the breach within 30
(thirty) days starting on the day after receipt of written notice from giving full details of the breach and requiring Sub-Licensee to remedy the breach and stating that a failure to remedy the breach may give rise to termination under clause 6.1;

  

	 	6.2.4	Sub-Licensee challenging the ownership and registration, continuing ownership or registration of the Trade Mark Rights in the name of owner of the Trade Mark Rights.

  

	7.	ASSIGNMENT 

  

	7.1	Sub-Licensee may, under no circumstances, assign, sub-licence or otherwise permit any third party to use the Trade Mark or the Logo in any way.

  

					
	Confidential	  	Page 23 of 27	  	

	8.	GENERAL 

  

	8.1	No variation of this Agreement (including this clause) is valid unless it is in writing and signed by or on behalf of each party. 

 

	8.2	This Agreement contains the entire agreement between the parties concerning the subject matter hereof and supersedes any pre-existing agreement and any oral or written
communications between the parties. 

  

	8.3	Any notice or other communication in connection with this Agreement must be in writing in the English language and must be delivered personally, sent by certified or
registered air-mail, postage prepaid or by facsimile (confirmed by such certified or registered mail) to the respective party at the address specified in the first paragraph hereof, or such other addresses as may be designated in writing by the
respective party. Notices shall be deemed effective on the date of mailing. 

  

	9.	GOVERNING LAW AND LANGUAGE 

  

	9.1	This Agreement is governed by the law of the England and Wales. 

  

			
	 EXECUTED by the parties

 
	  	
	 Signed by /s/ Gary Hulme— Director
 for and on behalf of
 INVIBIO LIMITED

/s/ Gary Hulme         Signature
	  	 Signed by /s/ Christophe Lavigne – President
 for and on behalf of
 LDRMEDICAL
 Christophe Lavigne         Signature

  

					
	Confidential	  	Page 24 of 27	  	

 SCHEDULE 1 
 Trade Mark Rights 
  

															
	 COUNTRY
	  	APPLICATION/
REGISTRATION NO.	  	FILING
       
 DATE        	 	  	MARK	  	    CLASSES    	 	  	STATUS
	 JAPAN
	  	4377047	  	 	18.03.99	  	  	PEEK-OPTIMA	  	 	10	  	  	GRANTED
	 SINGAPORE
	  	T99/04883H	  	 	12.05.99	  	  	PEEK-OPTIMA	  	 	10	  	  	PENDING
	 CTM
	  	1087592	  	 	22.02.99	  	  	PEEK-OPTIMA	  	 	1,10,17	  	  	GRANTED
	 HONG KONG
	  	BI1451	  	 	10.03.99	  	  	PEEK-OPTIMA	  	 	17	  	  	GRANTED
	 HONG KONG
	  	B07270	  	 	10.03.99	  	  	PEEK-OPTIMA	  	 	10	  	  	GRANTED
	 HONG KONG
	  	BI1450	  	 	10.03.99	  	  	PEEK-OPTIMA	  	 	1	  	  	GRANTED
	 JAPAN
	  	11-24513	  	 	18.03.99	  	  	PEEK-OPTIMA	  	 	1	  	  	PENDING
	 JAPAN
	  	4249593	  	 	18.03.99	  	  	PEEK-OPTIMA	  	 	17	  	  	GRANTED
	 SINGAPORE
	  	T99/04882Z	  	 	12.05.99	  	  	PEEK-OPTIMA	  	 	1	  	  	PENDING
	 SINGAPORE
	  	T99/04884F	  	 	12.05.99	  	  	PEEK-OPTIMA	  	 	17	  	  	PENDING
	 U.K.
	  	2190848	  	 	04.03.99	  	  	PEEK-OPTIMA	  	 	1,10,17	  	  	PENDING

  

					
	Confidential	  	Page 25 of 27	  	

					
	EXECUTED by the parties	  		  	
			
	 Signed by /s/ Gary Hulme, Director
 for and on behalf of
 INVIBIO LIMITED

/s/ Gary Hulme Signature
	  	 )
 )

)
  
	  	
			
	 Signed by Christophe Lavigne – President
 for and on behalf of
 LDRMEDICAL
 /s/ Christophe Lavigne Signature
	  	 )
 )

)
  
	  	

  

					
	Confidential	  	Page 26 of 27	  	

 APPENDIX 1 

Using the Invibio TM and PEEK-OPTIMA® Logos—A guide to Business Partners 

  

					
	Confidential	  	Page 27 of 27	  	

 10 November 2004 
 Mr Christophe Lavigne 
 LDR Medical 
 Technopole de L’aube—BP 2 
 10902 Troyes 

Cedex 9 
 France 

Dear Mr Lavigne: 
 Letter of Amendment in
respect of Supply Agreement between Invibio Ltd, and LDR Medical dated 31 January 2003 (the “Agreement”) 
 Following
discussions, we are writing to confirm that following discussions and pursuant to section 26.1 of the Agreement, we have agreed to make the following amendments to the Agreement. 
 In this letter capitalised words shall have the same defined meaning as in the Agreement. 
  

	1.	In Section 1—the definition of “Territory” shall be deleted. 

 

	2.	The first sentence in Clause 3.1 shall be amended to state that “This Agreement has a Term of eight (8) Years from the date of the Agreement, unless
terminated earlier pursuant to Clause 21. 

  

	3.	Clauses 10.3 and 10.4 shall be deleted. 

  

	4.	A new Clause 12.5 shall be added to the Agreement which shall read as follows: 

 At Buyer’s written request, Supplier shall provide a letter of entitlement to the United States Food and Drug Administration (“‘FDA”) and to Buyer to enable FDA to reference
Supplier’s master files on any FDA submission made by Buyer. The [***] as set out in Clause 12.4 shall [***] payable by Buyer on [***] falling after receipt by Buyer of such letter of entitlement but falling before the date of first receipt by
the Buyer of FDA approval to market a Buyer Product in the USA (“FDA Approval”). The [***] shall then [***] (the “[***]”) first payable by Buyer [***] and which amount of € [***] shall then be payable on each [***], during
the Term. Buyer shall promptly notify Supplier in writing upon receipt of such FDA Approval. 
  

	5.	The Agreement shall be amended to include the following Clause 13—[***]: 

 

	 	13.1	In addition to any other payments to be made by the Buyer to the Supplier under this Agreement, the Buyer shall, in respect of each Buyer Product sold, supplied or
otherwise made available by or on behalf of the Buyer, [***], pay the [***] listed against that Buyer Product in          Schedule 2. 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

	 	13.2	The [***] payable to the Supplier in respect of a sale of a Buyer Product by the Buyer to an Associated Company or to any third party otherwise associated with or
Acting in Concert with the Buyer shall be [***] 

  

	 	13.3	The Buyer shall, no later than [***], beginning on [***], pay all [***] payable under Clause 13.1 in respect of the preceding [***],[***], by electronic funds transfer
to such bank account as may be specified by the Supplier from time to time. For the avoidance of doubt, the amount of a [***] may only be taken into account [***] for the purpose of calculating the amount payable by the Buyer under this Clause

  

	 	13.4	The Buyer shall, at the same time as making the payment required by Clause 13.3, submit to the Supplier a report showing the quantities of Buyer Products, categorised
by Product Group, sold, supplied or otherwise made available during the previous calendar year together with their Net Invoice Prices. The Buyer shall keep full, true and accurate books of account, and all other records, including, without
limitation, physical stock records, reasonably necessary to verify each such report and shall permit the Supplier or a reputable firm of accountants nominated by the Supplier access to such books and records on reasonable prior notice during
business hours for such verification purposes. If during such a verification process any discrepancy between the reports previously submitted to the Supplier and the Buyer’s books and other records is discovered, the Buyer shall on demand pay
to the Supplier the amount of [***] then unpaid as a result of that discrepancy and all costs incurred by the Supplier in carrying out the audit. If the Supplier discovers a material discrepancy, it shall be entitled to terminate this Agreement with
immediate effect. 

  

	 	13.5	The Buyer shall not take any action, including, but without limitation, the transfer of any Buyer Products to any person other than the Buyer, intended to, or which
might have the effect of, avoiding the Buyer’s obligations to pay [***] under this Agreement. 

  

	 	13.6	The obligations under this Clause 13 shall continue in force for so long as [***]. 

 

	5.	Clause 19 shall be deleted in its entirety and shall be replaced with new Clause 19 which shall read as follows: 

Prior to making any Buyer Product commercially available in the United States of America, Buyer shall obtain and subsequently maintain,
during the subsequent entire term of its indemnification obligations hereunder, comprehensive liability insurance, including medical implant product liability coverage, in the minimum amounts of € 5,000,000 per occurrence for damage,
injury and/or death to persons (the “Insurance Policy”). Buyer shall provide Supplier with a certificate of insurance indicating the existence and coverage of the Insurance Policy, that all outstanding periodical premiums have been paid,
and indicating that the coverage shall not be cancelled nor modified unless at least thirty (30) calendar days prior written notice thereof has been provide to Supplier. Such certificate of insurance shall be provided on the Effective Date and
on each anniversary thereof during the entire term of Buyer’s indemnification obligations hereunder. In the event that the Insurance Policy is cancelled, or modified such that it does not include all requirements of this Clause, such
cancellation or modification shall constitute a material default and Supplier shall have the right to immediately terminate this Agreement without prior written notice as otherwise required under Clause 21.2.1. 

 

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

	6.	Clause 20 shall be deleted in its entirety and shall be replaced with new Clause 20 which shall read as follows: 

Buyer agrees to indemnify, defend and hold harmless Supplier and other members of its Group (including without limitation its and their
directors, officers, employees, agents, representatives and shareholders) from and against any and all claims by any third party, including any claims, actions, suits, proceedings, liabilities, obligations, losses, damages (including any fines,
penalties or punitive damages), settlement, interests, costs and expenses (including attorneys’ fees, court costs and other reasonable out-of-pocket expenses incurred in investigating, preparing or defending any of the foregoing or in enforcing
rights hereunder) resulting there from by reason of or in connection with or arising out of or relating to any sale, transfer. or use by any person of any Buyer Products or services sold or otherwise made available by Buyer or any related persons or
entities (including without limitation any current or former direct or indirect Parent or Subsidiary or any Affiliate or associate thereof) in which Stock Shape is incorporated or otherwise involved, except to the extent arising or resulting from
(i) any liability of Supplier for the failure of the Stock Shape to conform with the Supply Manufacturing Definition where such failure is proved to be the actual and proximate cause of the claimed personal injury or property damage, or
(ii) any liability of Supplier for the infringement by Stock Shape of the patents or other intellectual property rights of any person or entity other than Supplier, such patents and intellectual property rights limited to compositions and
excluding any methods of manufacture or devices or use thereof. 
 Any person or entity seeking indemnification hereunder must
promptly notify Buyer within sixty (60) calendar days of the date of actual notice of any claim for which it seeks indemnification, provided that any such failure shall not relieve Buyer of its obligations hereunder except to the extent that
Buyer is actually prejudiced by such failure to notify. In the event that Buyer shall be called upon to provide the indemnification set forth herein, Buyer shall control the defence, litigation and/or settlement of such claim (except to the extent
that any settlement involves some commitments, responsibilities and/or obligations on the part of Supplier, in which case such settlement shall require the prior written consent of Supplier), action or proceeding with attorneys of its choosing, and
Supplier and all other indemnified persons or entities shall cooperate as may reasonably be required by Buyer (but at Buyer’s expense in such defence, litigation and/or settlement). Supplier reserves the right to participate at its own cost in
any proceedings with counsel of its own choosing, provided that if Buyer fails to appoint suitably qualified counsel. Buyer shall be responsible for all attorney’s fees and costs incurred by or charged to Supplier. Supplier, Buyer and their
respective counsel will cooperate fully and make available all books, records, information and witnesses under their control and reasonably necessary or useful in connection with the defence of any such claim. Buyer shall not, in the defence of any
such claim or proceeding, except with the prior written consent of Supplier, consent to the entry of any judgment or enter into any settlement which would be to the financial or other detriment of Supplier. Buyer shall confer promptly with Supplier
concerning the terms of any proposed settlement or judgment arising in the course of such defence prior to consenting to the entry of any judgment or entering in any settlement. Buyer shall use all reasonable efforts to prevent Supplier from being
added as a defendant to any lawsuit involving or relating to Buyer Products, and to seek immediate dismissal or summary judgment of non-liability of Supplier for any lawsuit involving or relating to Buyer Products in which Supplier is a named
defendant, by employing defence mechanisms including, but not limited to, those set forth in the Biomaterials Access Assurance Act of 1998, as codified in 21 U.S.C. § 1601 et seq., and the bulk supplier and/or learned intermediary doctrines.

	7.	Schedule 2 - the following [***] shall be included for the Products: [***]: 

 

					
	 Product
	  	 Name
	  	Article
Number
	 [***]
	  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

					
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]
		  	 [***]
	  	[***]

  

	8.	Schedule 2 - [***] shall be included in the Agreement as follows: 

 For the above named [***] and [***] an [***] of [***]% of the [***], but not less than [***], shall apply for up to and including the first [***] sold, supplied or otherwise made available in the United
States of America, in any [***]. 
 For the above named [***] an [***] of [***]% of the [***], but not less than [***], shall
apply for any additional (in excess of [***]) [***] sold, supplied or otherwise made available in the United States of America in any [***]. 

Except as expressly provided in this letter of amendment, all other terms, conditions, and provisions of the Agreement shall continue in full force and
effect as provided therein. 
 This letter and all matters arising from or connected with it are governed by English Law. 

IN WITNESS WHEREOF, the parties have confirmed their acceptance of the contents of this Letter. 

 

			
	 /s/ Gary Hulme

For and on behalf of Invibio Limited

2006, November 5th
	  	 /s/ Christophe Lavigne
 For
and on behalf of LDR Medical
 2006, November 15th

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

			
		  	Invibio®
		
		  	biomaterial solutions
	23 November 2004	  	 Invibio LTD
 Technology Centre
Hillhouse International
 Thornton Cleveleys. Lancashire FY5 4QD UK
 Tel. +44 (0)1253 866812 Tel +44 (0)1253 851458

info@invibio.com                    
www.invibio.com

 Mr Christophe Lavigne 
 LDR Medical 
 Technopole de L’aube - BP 2 

10902 Troyes 
 Cedex 9 

France 
 Dear Mr Lavigne 

Letter of Amendment in respect of Supply Agreement between Invibio Ltd, and LDR Medical dated 31 January 2003 (the “Agreement”)

 Following discussions, we are writing to confirm that following discussions and pursuant to section 26.1 of the Agreement, we have agreed
to make the following amendments to the Agreement. 
  

	1.	Schedule 2 - the following [***] shall be included for the [***] and [***]: 

 

					
	 Product
	  	 Name
	  	Article
Number
	 [***]
	  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

					
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]

 This product list supersedes the product list scheduled in the previous letter of amendment dated 10 November 2004,
which will now be deleted from that letter of amendment. All other terms and conditions of that letter apply. 
 Except as expressly provided in
this letter of amendment, all other terms, conditions, and provisions of the Agreement shall continue in full force and effect as provided therein. 
 This letter and all matters arising from or connected with it are governed by English Law. 
  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 IN WITNESS WHEREOF, the parties have con finned their acceptance of the contents of this Letter 

 

			
	 /s/ Gary Hulme
 For and on
behalf of Invibio Limited
 Date    12/1/04
	  	 /s/ Christophe Lavigne
 For
and on behalf of LDR Medical
 Date    12/3/2004

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

			
	9 July 2008	  	 Invibio LTD
 Technology
Centre Hillhouse international
 Thornton Cleveleys. Lancashire FY5 4QD UK
 Tel. +44 (0)1253 866812 Tel +44 (0)1253 851458

info@invibio.com                       
  www.invibio.com

 Mr. Michael Labrum 
 LDR Medical 
 Technopole de L’aube - BP 2 

10902 Troyes 
 Cedex 9 

France 
 Dear Mr. Michael Labrum,

 Letter of Amendment in respect of Supply Agreement between Invibio Ltd, and LDR Medical dated 31 January 2003 (the
“Agreement”). 
 Following our discussions we are writing to confirm that pursuant to clause 26.1 of the Agreement we have agreed
to make the following amendments to the Agreement: 
  

	1.	Clause 11.1 of the Agreement shall be amended so that Stock Shape of grade LT1R6 is included at an initial price of € [***] per meter, with a minimum order
quantity of [***] meters per order with the exception of the first order which may be for a minimum order quantity of [***] meters. 

  

	2.	Schedule 1 Part II of the Agreement shall be amended to incorporate the Supplier’s Supply Manufacturing Definitions for Stock Shape grade LT1R6, as attached to
this Letter. 

  

	3.	Schedule 2, Buyer Products shall be amended to include the following Buyer Products: LDR-R Rod Easyspine PEEK 

 

	4.	Schedule 2, [***] shall be amended for the above named implant [***] of [***]% of the [***] shall apply for any [***] sold, supplied or otherwise made available in the
United States of America in any [***]. 

 This letter and all mailers arising from or connected with it are governed by English
Law. 
 Please confirm your acceptance of this Letter by signing and dating the enclosed copy. 

In WITNESS WHEREOF, the parties have confirmed their acceptance of the contents of this Letter 

 

					
	  	 		 	/s/ Eric Vigneron-DGA
	For and on behalf of Invibio Ltd	 		 	For and on behalf of LDR Medical

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

					
	PEEK-OPTIMA ®	  		  	Grade: LTIR6
	SPECIFICATION	  		  	Page: I of I
	MANUAL	  	Invibio®	  	Revision: I
	ISSUE I	  	biomaterial solutions	  	Date:19th May 2006

  
  

 

			
	PEEK-OPTIMA LT1 Extruded Rod	  	 Specification Ref. INV 08

 Supply Manufacturing Definition 
 Grade: LTIR6 
 Diameter: 6.00mm (+0.1mm/+O.4mm) 

Sampling and testing: 
 The tests shown
below shall be performed by supplier on material taken from the start and end of each production batch. The batch shall meet the requirements of this Supply Manufacturing Definition when the results of these tests agree with the values shown below.

  

							
	 PROPERTY
	  	TEST METHOD	 	        UNITS        	 	SPECIFICATION
	 Tensile strength at Yield
	  	[***]	 	[***]	 	[***]
	 Tensile Elongation at Break
	  	[***]	 	[***]%	 	[***]
	 Density
	  	[***]
 [***]
	 	[***]  
	 	[***]  

	 DSC

Tg (Onset)
 Tc (Recrystallistion)
 Tm (Melt)
	  	[***]
 [***]
	 	[***]  
	 	[***]
 [***]
 [***]

	 Cytotoxicity
	  	[***]	 	[***]	 	[***]

 Notes: 
  

	1.	The supplied rod may contain levels of black speck intrinsic to all extruded rod stock. 

 

	2.	Some surface discoloration and/or texture is common and this can be removed by machining. 

 

	3.	Gel Permeation Chromatography 

 The material displays the characteristic molecular weight distribution curve for PEEK-OPTIMA ® LTI, corresponding with historical GPC data; REF/SPECTRM/LTI/GPC 
  

	4.	FTIR. 

 The
material displays the characteristic FTIR spectrum for PEEK-OPTIMA ® LTI, corresponding with an historical
standard spectrum; REF/SPECTRUM/LT1/FTIR 
  

	5.	 The base material will be PEEK-OPTIMA ® LTI conforming to specification INV 01 

Specification Approval 
  

			
	Margaret Such
                                         
                       	  	Date: 19th May 2006
	Global Quality Manager	  	

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

			
	17 June 2009	  	 Invibio LTD
 Technology
Centre Hillhouse international
 Thornton Cleveleys. Lancashire FY5 4QD UK
 Tel. +44 (0)1253 866812 Tel +44 (0)1253 851458
 info@invibio.com
                         www.invibio.com

 Mr Michael Labrum 
 LDR Medical 
 Technopole de L’aube - BP 2 

10902 Troyes 
 Cedex 9 

France 
 Dear Mr Michael Labrum, 

Letter of Amendment in respect of Supply Agreement between Invibio Ltd, and LDR Medical dated 31 January 2003 (the “Agreement”).

 Following our discussions we are writing to confirm that pursuant to clause 27.1 of the Agreement we have agreed to make the following
amendments to the Agreement: 
  

	 	1.	The parties agree to extend the terms of the Agreement in its entirety with all terms and conditions remaining unchanged, except as stated below, for a further term of
[***] (the “Term”), expiring on [***]. 

  

	 	2.	 Clause 11.1 of the Agreement shall be amended so that the price for PEEK-OPTIMA® Stock Shape is as follows: 

Grade L T1 R20 shall increase by an additional [***]% to € [***] per meter with effect from 1 July 2009, no further increase
shall apply until 1 June 2011. 
 Grade L T1 R30 shall increase by an additional [***]% to € [***] per meter with
effect from 1 July 2009, then by an additional [***]% to € [***] per meter with effect from 1 July 2010, no further increase shall apply until 1 July 2012. 

 

	 	3.	A new Clause 12.6 shall be added to the Agreement which shall read as follows: 

 12.6 Subject to Standard Condition 3, in consideration for Supplier’s provision, [***], other information relating to the general performance and/or other general physical characteristics of the
Biomaterials and the Stock Shape, and in addition to any other payments required to be made to Supplier by Buyer under this Agreement the Buyer shall pay to the Supplier [***] as follows (the “[***]”): 

12.6.1 The first [***] of € [***] shall be due and payable upon [***], 

12.6.2 The second [***] of € [***] shall be paid by Buyer and received in cleared funds by Supplier within [***]. 

 

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

	4.	Schedule 2, [***] shall be amended for sales in [***] as follows: 

 Up to € [***] in sales: [***]% of the [***], with a minimum of € [***]. 

€ [***] up to € [***] in sales: [***]% of the [***], with a minimum of € [***]. 

€ [***] onwards in sales: [***]% of the [***], with a minimum of € [***]. 

 

	 	5.	The first sentence of Clause 13.3 shall be replaced as follows: 

 The Buyer shall, no later than [***], pay all [***] payable under clause 13.1 in respect of the [***], less the amount of the most recently made [***], by electronic funds transfer to such bank account as
may be specified by the Supplier from time to time. The [***] shall be due and payable in [***] and shall include all those [***]. From [***] onwards the [***] shall made for the [***]. 
 This letter and all mailers arising from or connected with it are governed by English Law. 

Please confirm your acceptance of this Letter by signing and dating the enclosed copy. 
 In WITNESS WHEREOF, the parties have confirmed their acceptance of the contents of this Letter 
  

			
	/s/ Gary Hulme	  	/s/ Eric Vigneron-DGA
	For and on behalf of Invibio Ltd	  	For and on behalf of LDR Medical

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

			
	07 December 2011	  	 Invibio Inc
 300
Conshohocken State Road Suite 120
 West Conshohocken, PA 19428
 USA
 Tel. (484) 342-6004 Toll-free 866-INVIBIO

Fax: (484) 342-6005

info@invibio.com                       
  www.invibio.com

 LDR Medical 

Technopole de L’aube - BP 2 
 10902 Troyes

 Cedex 9 
 France 

Dear Sir, 
 Letter of Amendment in respect
of Supply Agreement between Invibio Ltd, and LDR Medical dated 31 January 2003 (the “Agreement”). 
 Following our
discussions we are writing to confirm that pursuant to clause 26.1 of the Agreement we have agreed to make the following amendments to the Agreement: 
  

	1.	The definition of Biomaterials shall be amended to read in its entirety as follows: 

“Biomaterials” shall mean Supplier’s [***]; 

 

	2.	A new definition of Buyer Specification shall be included to read as follows: 

 “Buyer Specifications” shall mean the [***], provided by Buyer, that specify the [***] in the form of [***], as referenced in Schedule 5-1 attached, that Supplier shall meet prior
to shipping such Biomaterials to Buyer. Such Buyer Specifications may be changed or modified, amended or supplemented from time to time by written approval between both parties [***]; 

 

	3.	Section 2.1 of the Agreement shall be amended to include the following sentence: 

“Certain additional terms relating to the [***], which comprise Biomaterials, manufactured in accordance with the Buyer Specification
are set forth in Schedules 4-1 attached, which may be amended by mutual written agreement by the parties.” 
  

	4.	Clause 11 shall be amended so that for [***] in Schedule 5-1 , it will be included at [***] detailed in Schedule 4-1 attached. This [***] is for the [***] specified in
Schedule 4-1 only. Any further volume required will be discussed between both parties and pricing adjusted accordingly. 

  

	5.	All references to “Stock Shape” within the agreement shall be amended to read “Stock Shape or Biomaterials”; and all references to “Supply
Manufacturing Definition” within the agreement shall be amended to read “Supply Manufacturing Definition or Specifications or Buyer Specifications, as the case may be”. 

Except as expressly provided in this letter of amendment, all other terms, conditions, and provisions of the Agreement shall continue in full force and
effect as provided therein. 
 This letter shall be governed by and construed in accordance with the laws of the state of Colorado without
regard to the conflict of law provisions thereof. 
  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 IN WITNESS WHEREOF, the parties have confirmed their acceptance of the contents of this letter. 

 

					
	 	 		  	/s/ Eric Vigneron-DGA
	For and on behalf of	 		  	For and on behalf of
	Invibio, Inc.	 		  	LDR Medical
			
	Date:
                                         
     	 		  	Date: 12/08/2011

 SCHEDULE 4-1 
 [***] IN ACCORDANCE WITH THE BUYER 
 SPECIFICATION 

PRICING AND ADDITIONAL TERMS 

BIOMATERIALS: 
  

							
	 Part number
	  	Description	 	Material
Grade	 	Supply
Quantity
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]

 PROCESSES: [***] ([***]mm) 
 [***] 
 [***] 
 COMMERCIAL SUPPLY PRICE: 
 PRICE PER UNIT: €[***] each 

For the avoidance of doubt, the [***] is applicable for the [***]. 
 Buyer shall pay each invoice in full within [***] cleared funds in EUROS to the bank account notified from time to time by Supplier. 
 ADDITIONAL COMMERCIAL TERMS 
 Long term Unit Pricing, Supplier and
Buyer shall discuss and agree [***] following the [***], and Exhibit E shall be amended appropriately. 
 Validated Processes,
Supplier will complete process validation of the [***] in accordance with a [***]. 
  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 SCHEDULE 5-1 
 The Buyer Specification 
  

					
	 Part number
	  	 Description
	  	Material
Grade
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

 Buyer Specifications: 
  

			
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 The drawing and current drawing revision and specification shall be controlled in Invibio’s Quality system. Any
changes to the drawing revision may require amendment to this agreement of failure to supply. 
 All purchase orders should reference the part
number, drawing number and current drawing revision number. 
  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.EX-10.28

 Exhibit 10.28 

 

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 1
/12

  

	[***]	indicates material that has been omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission. A complete copy of this
agreement, including redacted portions so indicated, has been filed separately with the Securities Exchange Commission. 

 Between 
 GREATBATCH MEDICAL SAS 

Z.I. La Vendue - BP 88 
 52000 Chaumont 
 And 

 
 

 
 LDR MEDICAL 
 4, Rue Gustave Eiffel 
 10430 ROSIÈRES PRES
TROYES 
 [here and on all subsequent pages: 
 two sets of initials] 

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 2
/12

  

 TABLE OF CONTENTS 

 

					
	 1. Purpose
	  	 	3	  
		
	 2. Scope of application
	  	 	3	  
		
	 2.1 Products
	  	 	4	  
		
	 2.2 Site
	  	 	4	  
		
	 3. Duration
	  	 	4	  
		
	 4. Compliance with requirements
	  	 	5	  
		
	 5. Deadlines [***]
	  	 	5	  
		
	 6. Responsibility for design changes
	  	 	5	  
		
	 7. Non-Conformity
	  	 	6	  
		
	 8. Contractual and financial conditions
	  	 	6	  
		
	 8.1 Products
	  	 	6	  
		
	 8.2 Projected LDR MEDICAL needs
	  	 	6	  
		
	 8.3 Batch size
	  	 	7	  
		
	 8.4 Prices
	  	 	7	  
		
	 8.5 Billing
	  	 	7	  
		
	 8.6 Settlement
	  	 	7	  
		
	 9. Packaging and shipping
	  	 	7	  
		
	 10. Assignment of jurisdiction
	  	 	8	  
		
	 11. Termination
	  	 	8	  
		
	 12. Confidentiality
	  	 	8	  
		
	 13. Disputes - litigation
	  	 	10	  
		
	 14. Sundry
	  	 	10	  
		
	 15. Limitations
	  	 	10	  
		
	 16. Limited guarantee
	  	 	11	  
		
	 17. Force majeure
	  	 	12	  

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 3
/12

  

	1.	Purpose 

 The purpose of
this agreement is to define the conditions of the commercial agreement 
 Between: 

The party of the first part, the French company LDR MEDICAL, a company duly organized and governed by French law, with share
capital of €215,357.40, having corporate headquarters at 4 rue Gustave Eiffel, Rosières Près Troyes, registered with the RCS [Trade and Corporate Registry] of Troyes under No. 433 924 529, acting on its own behalf as well as
that of its subsidiaries, Represented by its Deputy Chief Executive Officer, Mr. Eric Vigneron, Hereinafter referred to as “LDR MEDICAL” 
 And 
 The party of the second part, the French company GREATBATCH MEDICAL
SAS, a company duly organized and governed by French law, with share capital of €37,000, having corporate headquarters at Z.I. de la Vendue 52000 Chaumont, registered with the RCS of Chaumont under No. 499 235 018, Represented by its
Europe CEO, Mr. Patrick Gamet, Hereinafter referred to as the “Supplier” 
  

	2.	Scope of application 

This agreement, including Appendices 1 and 2, shall take effect upon its signing by the parties. The terms of this agreement
shall prevail over all other previous provisions (with the exception of CC SST GB 02), as well as the two parties’ general purchase and sale conditions. 
 The purpose of this agreement is to set forth the conditions for order placement, manufacture and delivery of the products listed in Appendix 1 to permit LDR MEDICAL to supply its customers on a
timely basis and in the appropriate quantities. 

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 4
/12

  

 Orders shall be placed over the GREATBATCH MEDICAL SAS site in Orvin, Switzerland, to
the following address: 
 GREATBATCH MEDICAL SAS 
 L’Echelette 7 
 2534 Orvin 

SWITZERLAND 
  

	 	2.1	Products 

 The agreement
applies to the specific components (“products”) listed in Appendix 1 
  

	 	2.2	Site 

 The
“products” shall be delivered to the following address: 
 LDR Médical 

4, Rue Gustave Eiffel 
 10430 ROSIÈRE PRES TROYES 

FRANCE 
  

	3.	Duration 

 This agreement
shall enter into force on the date of its signing by the parties, for a duration of 48 months. Subsequently, each LDR MEDICAL order shall reference it as follows: 
 CC FRN xxxx 01 of yy/yy/yyyy, where x identifies the name of the “Supplier” and y designates the date in dd/mm/yyyy format, noting the index of the version of this agreement approved by the two
parties. 
 Note: the index shown in the page footer [sic] of this document corresponds to the index of the
original LDR MEDICAL document not yet signed. 
 The agreement shall be renewed in the form of an addendum, and shall occur no
later than six months prior to the anniversary date of this agreement. Cancellation by either party shall be subject to a prior notice period of eighteen months. Cancellation must be communicated by registered letter with acknowledgement of receipt.

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 5
/12

  

	4.	Compliance with requirements 

 The “Supplier” undertakes to manufacture the “products” ordered by LDR MEDICAL in accordance with the requirements specified in the plans, specification sheets and/or purchase orders,
as agreed to in writing by the “Supplier.” 
 The products listed in Appendix 1 shall be delivered to LDR
MEDICAL and shall not be subject to systematic monitoring. Thus, the “Supplier” shall be responsible for ensuring that all internal monitoring to ensure high quality has been performed. 

An audit shall be carried out [***] by LDR MEDICAL at the “Supplier’s” facilities to ensure that the entire manufacturing
process is in order. 
  

	5.	Deadlines [***] 

 The
“Supplier” is required to deliver the “products” within the period specified in its Acknowledgement of Receipt of Order as accepted by LDR MEDICAL. 
 [***] 
  

	6.	Responsibility for design changes 

 In the event of elimination of a product, or any other order cancellation by LDR MEDICAL, LDR MEDICAL shall notify the “Supplier” thereof in writing. 

LDR MEDICAL undertakes to purchase finished products, products in production and semi-finished products from the
“Supplier’s” subcontractors and from the “Supplier” as a function of the commitment levels described in Appendix 2, as well as purchased materials and non-cancellable orders from the “Supplier’s”
suppliers. 
 In the event that a product is subsequently changed, LDR MEDICAL shall so notify the supplier in writing.

 Within [***], the “Supplier” must send to LDR MEDICAL a statement of production inventory (number of finished units
in inventory, status of items in production). 
 LDR MEDICAL shall issue instructions in accordance with the status of products
in production. 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 6
/12

  

	7.	Non-Conformity 

Non-conforming delivered products shall be handled in accordance with the conditions mentioned in subcontracting specification sheet CC
SST GB 02. 
  

	8.	Contractual and financial conditions 

  

	 	8.1	Products 

 All
“products” to be delivered by the “Supplier” are listed in Appendix 1. 
 Order processing shall be
managed in accordance with the conditions specified in subcontracting specifications sheet CC SST GB 02. 
  

	 	8.2	Projected LDR MEDICAL needs 

 LDR MEDICAL’s annual needs for [***] are as listed in Appendix 2. A table also defines LDR MEDICAL’s [***] needs covering the launch of MOBI C Plug & Fit in the United States.

 It is understood that the desired delivery dates may be subject to adjustment by LDR MEDICAL depending upon actual market
needs. 
 These adjustments may consist of a range of [***] but may not occur within fewer than [***] prior to the delivery dates
defined in Appendix 2. 
 Further, quantities may be subject to fluctuations of [***]. 

LDR MEDICAL undertakes to supply all volumes listed in Appendix 2, attached, during the fiscal year (or no later than two months
after its end). 
 Each year, during the final quarter of year N, LDR MEDICAL shall send to the “Supplier” the
projected annual orders for year N+1 (with the same quantity range of [***] as defined above). 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 7
/12

  

	 	8.3	Batch size 

 It has been
agreed that batch size shall be: 
  

	 	•	 	 a minimum of [***] units for MOBI-C prostheses 

  

	 	•	 	 a minimum of [***] units for ROI-C cages 

  

	 	8.4	Prices 

 The list of
negotiated prices is provided in Appendix 1. 
 Prices are firm and applicable for the duration of the agreement.

 Prices, expressed in euros, are understood as being net of taxes. 

 

	 	8.5	Billing 

 For each
delivery, an invoice covering all data contained in the order must be prepared and sent to LDR MEDICAL. 
  

	 	8.6	Settlement 

 LDR MEDICAL
shall pay the “Supplier” the amount of each invoice, [***] calendar days after its issuance date, provided that the delivered products are found to be in compliance. In the event of non-compliance, the invoice settlement time is as
detailed in subcontracting specification sheet CC SST BG 02. 
  

	9.	Packaging and shipping 

The “Supplier” shall ship depending on the batch sizes specified above in Paragraph 8.3. 

Delivery conditions are as defined in subcontracting specification sheet CC SST BG 02. 

Product title shall transfer to LDR MEDICAL at such time as the product leaves the “Supplier’s” premises. 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 8
/12

  

	10.	Assignment of jurisdiction 

Any dispute concerning this agreement that cannot be settled out of court shall be considered and interpreted in accordance with French
law except with regard to the application of clauses relative to conflicts between laws. In this case, the courts of Troyes alone shall be deemed competent. 
  

	11.	Termination 

 This
agreement may be terminated by either party in the event of material breach by the other of any of the obligations for which it is liable under this agreement. To this end, the party deeming itself injured shall send written notification to the
party in breach, and if the breach is not remedied within one (1) month after receipt of such notification, the injured party shall be entitled to terminate this agreement. 

Either party may, at its discretion, immediately cancel this agreement subject to written notification to the other party, in the event of
bankruptcy, insolvency, disposal in favor of creditors or similar proceedings relating to the liquidation or dissolution of the other party. 
  

	12.	Confidentiality 

 Pursuant
to this instrument, confidential and exclusive information (hereinafter referred to as “Confidential Information”) disclosed between the parties shall be provided in writing or, if transmitted orally, shall be provided in writing within
thirty (30) days after its disclosure, and shall bear the visible label “Confidential;” notwithstanding the above, it shall be understood at all times that breach by either party of its obligation to mark information as
“Confidential Information” shall not, however, release such party from its obligation to treat such information as Confidential Information in accordance with the conditions of this Section. Such Confidential Information shall include, but
not be limited to, the conditions and provisions of this Agreement. Confidential Information shall be protected by the recipient to the same extent as if it were its own information; it shall not be provided to third parties; and it shall be made
available solely to employees, independent contractors and/or agents of the recipient who have a need to know such Confidential Information as part of the execution of said party’s obligations pursuant to this instrument, who have been informed
by the recipient of the confidential nature of the information and who have signed or have agreed to sign a confidentiality agreement containing conditions largely similar to those presented in this Section. The recipient shall use the issuer’s
Confidential Information solely for purposes of executing its obligations under this instrument or in accordance with the authorizations of this Agreement. All Confidential Information shall remain the property of the issuer and the recipient shall
return it to the issuer within thirty (30) days after receipt of a written request from the issuer or within thirty (30) days after the cancellation of this 

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 9
/12

  

 
Agreement. Notwithstanding the above, the recipient may retain one copy of such Confidential Information (a) for purposes of ensuring the party’s rights and obligations with regard to
such Confidential Information, or (b) if the recipient’s legal advisors deem that the recipient is required to retain a copy of the Confidential Information under applicable law. The reciprocal confidentiality obligations set forth in this
Section shall apply for the entire duration of this Agreement and for five (5) years after cancellation or expiration of this Agreement. The Confidential Information shall not include information: 

(i) that is or subsequently becomes accessible to the public without that being due to breach of any confidentiality
obligation under this Agreement; 
 (ii) that is already known to the recipient, as demonstrated in written
documents previously in its possession; 
 (iii) that has been provided to the recipient by a third party in
violation of a confidentiality obligation to the issuer; 
 (iv) that is or was created by the recipient or on
its behalf without relying on the issuer’s Confidential Information; 
 (v) that is used with the
issuer’s written authorization in the context of applications for patent, copyright or any other intellectual property protection; or 
 (vi) approved in writing for publication by each party. 

Notwithstanding the above, each party may provide Confidential Information to the extent that its disclosure is required:
(a) under applicable law relative to the manufacture or sale of Products or for any other reason, or (b) by ruling of a competent court, provided that the issuer receives sufficient advance notification for such party to be able to appeal
the court’s ruling. 

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 10
/12

  

	13.	Disputes - litigation 

 In
the event of a dispute arising under this agreement that is unable to be resolved quickly during the normal course of business, authorized representatives of the parties shall quickly meet with a view to resolving the problem informally. 

In the event the parties’ authorized representatives are unable to resolve the problem within a reasonable period of two
(2) months after occurrence of the dispute, it shall be brought before the District Court (Tribunal de Grande Instance) of Troyes. 
  

	14.	Sundry 

 In the event that
a provision of this agreement is declared invalid, illegal or unenforceable, such a ruling shall not affect the validity of the remaining terms of this agreement. 
 This agreement constitutes the entire commitment of the parties with regard to its purpose, and replaces any other prior agreements and commitments, written or oral, of the parties with regard to the
purpose of this agreement. 
 Any amendment to the agreement must be made through a written instrument signed by the parties.

 This agreement was drawn up in French and English. In the event of discrepancy between the terms of the English and French
versions of this agreement, the French version of the agreement shall prevail. 
 The appendices to this agreement form an
integral part of this agreement. 
 Each party has prepared this agreement for execution in triplicate by its respective
representative. 
  

	15.	Limitations 

NOTWITHSTANDING ANY STIPULATION OF THIS AGREEMENT TO THE CONTRARY, UNDER NO CIRCUMSTANCES SHALL THE SUPPLIER’S TOTAL LIABILITY UNDER
THIS AGREEMENT EXCEED [***] UNDER THIS AGREEMENT, UNLESS THE LIABILITY DERIVES FROM OR IS RELATED TO ANY PRODUCT OR SERVICE SUPPLIED BY [***], IN WHICH CASE THE SUPPLIER’S TOTAL LIABILITY SHALL NOT EXCEED (A) [***] UNDER THIS AGREEMENT, OR
(B) [***], WHICHEVER AMOUNT IS LESS 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 11
/12

  

	16.	Limited guarantee 

 For
[***] following use of the product, the Supplier guarantees that each Product sold under this Agreement will conform to the applicable Specifications and be free of any material or manufacturing defect. Notwithstanding any stipulation to the
contrary in this Agreement, the Supplier’s guarantee pursuant to this instrument shall be void if any repair, alteration, modification or work has been done to such Product or to the extent that any alleged defect is the result of abuse,
misuse, incorrect storage or maintenance, or accident, action or inaction by any party other than the Supplier. Further, the Supplier shall not be responsible for (a) the quality or condition of any material supplied by or through LDR MEDICAL,
or (b) any defect provided it is due to use not consistent with applicable instructions. Pursuant to the above, if a Product is not as guaranteed and LDR MEDICAL notifies the Supplier in writing and returns such Product to the Supplier within
30 days after the discovery by LDR MEDICAL, the Supplier, at its discretion, shall quickly repair or replace the defective Product or reimburse the purchase price of the Product. Prior to return of a Product to the Supplier, LDR MEDICAL must contact
the Supplier’s customer service representative and obtain an RMA number. LDR MEDICAL may only return articles and quantities approved through the RMA. Any such repaired or replaced Product shall be re-shipped to LDR MEDICAL at the
Supplier’s sole expense. Such exclusive remedy shall not be considered as having violated the essential purpose insofar as the Supplier is willing and able to repair or replace a defective Product or to reimburse the purchase price in the
stipulated fashion. REPAIR OR REPLACEMENT OF THE PRODUCT OR REIMBURSEMENT OF THE PURCHASE PRICE AS STIPULATED UNDER THIS LIMITED GUARANTEE IS A REMEDY EXCLUSIVE TO LDR MEDICAL. THE GUARANTEES IN THIS SECTION REPLACE ANY OTHER GUARANTEE, EXPRESS OR
IMPLIED, MANDATORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO GUARANTEES OF MERCHANDISE QUALITY, COMPLIANCE AND FITNESS FOR A SPECIFIC USE. 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	COMMERCIAL SUPPLIER AGREEMENT 	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	 Page
 12
/12

  

	17.	Force majeure 

Neither party shall be in default under this Agreement in the event of any breach of any of its obligations under this Agreement if such
breach results from events outside the control of such party and not attributable to fault or negligence by such party, including but not limited to any natural disaster, acts of a public enemy, terrorism, act of government, fire, flood, earthquake,
epidemic, quarantine, embargo of merchandise and failure by carriers. If it appears that execution by either party under this Agreement might be delayed by a case of force majeure, such party shall inform the other party thereof as quickly as
possible. During a period when execution by one of the parties of its obligations under this Agreement is suspended due to a case of force majeure, the other party may also suspend execution of all or part of its obligations under this
instrument (other than the obligation to pay any amount owed) provided that such suspension is commercially reasonable. 
 In two
original copies at Troyes, November 28, 2012. 
  

			
	 Company name: GREATBATCH MEDICAL SAS
	  	Company name: LDR Médical
		
	 Commercial stamp
	  	Commercial stamp
		  	[stamp]
		  	LDR
		  	a passion for innovation
		  	HOTEL DE BUREAUX 1
		  	4 rue Gustave Eiffel
		  	10430 Rosières-Près-Troyes
	 Tel.: (+33) 03 25 82 32 63 – Fax: (+33) 03 25 82 33 71

  

							
	Name and title of signatory	  	    Name and title of signatory
	        [handwritten] P. GAMET, VP, GBM Europe	  		  	E. VIGNERON
				
	Signature        	  	    [signature]	  	    Signature        	  	[signature]

							
	LDR Médical
	 	 COMMERCIAL SUPPLIER AGREEMENT

  
 APPENDIX 01
	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	Page 1/2

 

 

 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	 COMMERCIAL SUPPLIER
AGREEMENT
  
 APPENDIX
01
	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	Page 2/2

 

  
 

 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	 COMMERCIAL SUPPLIER AGREEMENT

  
 APPENDIX 02
	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	Page 1/2

 

 PROJECTIONS 
 MOBI C Plug & Fit USA: 
  

	 	•	 	 2012: [***] 

  

	 	•	 	 2013: [***] implants 

  

	 	•	 	 2014: [***] implants 

  

	 	•	 	 2015: [***] implants 

See breakdown by month on page 2/2 

ROI C (anatomical and/or lordosis) 
  

	 	•	 	 2012: [***] 

  

	 	•	 	 2013: [***] implants [***] 

  

	 	•	 	 2014: [***] implants 

  

	 	•	 	 2015: [***] implants 

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

							
	LDR Médical
	 	 COMMERCIAL SUPPLIER AGREEMENT

  
 APPENDIX 02
	 	Document  	 	Ref.: CC FRN GB 01
	 	 	 	Index: 10/15/2012
	

 	 	 	 	AM No.:
	 	 	 	Page 2/2

  

																																																													
	 MOBI
 C
P&F
 USA
	 	 Jul

13
	 	 Aug

13
	 	 Sep

13
	 	 Oct

13
	 	 Nov

13
	 	 Dec

13
	 	 Jan

14
	 	 Feb

14
	 	 Mar

14
	 	 Apr

14
	 	 May

14
	 	 Jun

14
	 	 Jul

14
	 	 Aug

14
	 	 Sep

14
	 	 Oct

14
	 	 Nov

14
	 	 Dec

14
	 	 Jan
15
	 	 Feb

15
	 	 Mar

15
	 	 Apr

15
	 	 May

15
	 	 Jun

15
	 	 Jul

15
	 	 Aug

15
	 	 Sep

15
	 	 Oct

15
	 	 Nov

15
	 	 Dec

15

	 Total Implants Required
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 [***] 
 [***]

  

	[***]	Portions of this page have been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]